Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990040/S034

TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural Set

Cerenovus, Inc. · Decision date Dec 16, 2025

FDA DECISIONP990040/S034

What did the FDA approve?

FDA records P990040/S034 as a supplement to PMA P990040, with the supplement type “Panel Track”. The recorded decision is approval, dated Dec 16, 2025.

FDA approval order statement

The TRUFILL n-BCA Liquid Embolic System is indicated for the embolization of cerebral arteriovenous malformations (AVMs) when pre-surgical devascularization is desired and for embolization of the Middle Meningeal Artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (SDH) as an adjunct to surgery.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Neurology
Decision date
Dec 16, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P990040/S034
Regulatory pathway
PMA supplement
Product code
SGU
Decision code
APPR
Decision date
Dec 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Neurovascular Liquid Embolic Agent.

Product code
SGU
FDA device class
3

For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P990040 · Original PMA

    TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM

  2. P990040/S034 received

    Application receipt date recorded by FDA.

  3. P990040/S036 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

  4. P990040/S034 · FDA decision

    Panel Track

  5. P990040/S038 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

  6. P990040/S037 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990040

Product / regulatory recordCompanyPathwayDecision dateSource
Cerenovus, Inc.PMA approvalSep 25, 2000FDA
Cerenovus, Inc.PMA supplementAug 22, 2025FDA
Cerenovus, Inc.PMA supplementMay 26, 2026FDA
Cerenovus, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code SGU

Product / regulatory recordCompanyPathwayDecision dateSource
Balt USA, LLCPMA supplementOct 16, 2026FDA
Balt USA, LLCPMA supplementSep 9, 2026FDA
Ev3 NeurovascularPMA supplementAug 5, 2026FDA
Balt USA, LLCPMA approvalJan 30, 2026FDA
Ev3 NeurovascularPMA supplementDec 8, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerenovus, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6303 Waterford District Dr., Suite 315, Miami, FL, 33126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records